Format

Send to

Choose Destination
Expert Rev Vaccines. 2009 Jul;8(7):851-61. doi: 10.1586/erv.09.48.

Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

Author information

1
Department of Social Medicine, University of Bristol, Canynge Hall, Bristol, UK. caroline.trotter@bristol.ac.uk

Abstract

Effective vaccines provide direct protection to immunized individuals, but may also provide benefits to unvaccinated individuals by reducing transmission and thereby lowering the risk of infection. Such herd immunity effects have been demonstrated following the introduction of meningococcal serogroup C conjugate (MCC) vaccines, with reductions in disease attack rates in unimmunized individuals and significantly lower serogroup C carriage attributable to the vaccine introduction. In the UK, targeting teenagers for immunization was crucial in maximizing indirect effects, as most meningococcal transmission occurs in this age group. Questions remain regarding the duration of herd protection and the most appropriate long-term immunization strategies. The magnitude of the herd effects following MCC vaccination was largely unanticipated, and has important consequences for the design and evaluation of new meningococcal vaccines.

PMID:
19538112
PMCID:
PMC3988355
DOI:
10.1586/erv.09.48
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center